Pharvaris N.V. (PHVS)
NASDAQ: PHVS · IEX Real-Time Price · USD
23.35
+0.58 (2.55%)
At close: Apr 26, 2024, 4:00 PM
24.60
+1.25 (5.35%)
After-hours: Apr 26, 2024, 4:03 PM EDT
Pharvaris Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
82
Market Cap
1.26B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Brookdale Senior Living | 3.02B |
| Omnicell | 1.15B |
| Pacira BioSciences | 674.98M |
| Ironwood Pharmaceuticals | 442.74M |
| Kiniksa Pharmaceuticals | 301.77M |
| Xencor | 168.34M |
| Spyre Therapeutics | 886.00K |
PHVS News
- 17 days ago - Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 17 days ago - Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer - GlobeNewsWire
- 24 days ago - Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference - GlobeNewsWire
- 5 weeks ago - Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses - GlobeNewsWire
- 7 weeks ago - Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses - GlobeNewsWire
- 7 weeks ago - Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 - GlobeNewsWire
- 2 months ago - Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Pharvaris Announces Extraordinary Meeting of Shareholders - GlobeNewsWire